Diego M. Gonzalez

Littespark011. Belzutifan plus Lenvatinib in second line RCC against Cabozantinib. Os not yet reached. But some pts have pretty long term responses .Impressive data @DrChoueiri @dr_yakupergun @tompowles1 @OncBrothers @OncoAlert @ASCO #GU26

Closing the most important meeting in LATAM Oncology! Thank you @Prof_Nadia_H @AndresC27622123 @curijoey @myESMO @LizzySmyth1 for the amazing support! Hope to see you soon in Colombia, your home.

@DrFRodriguezCov @fedelosco @BourlonMaite @GustavoVillold4 @urologohector @jardim_denis Latin American experts together, gathered to provide important recommendations for our patients in our reality! Thank you all for this colaboration! @achoHematoYOnco @SCUColombia @ASCO @myESMO @Uromigos

Outcomes of Complete Responders From First-line Therapy in Metastatic Renal Cell Carcinoma in the Real World: An Analysis From the International Metastatic Renal Cell Carcinoma Database Consortium buff.ly/PAi0wVi In this real-world IMDC analysis, complete responses (CR) to first-line therapy in metastatic renal cell carcinoma were uncommon but associated with excellent survival across IO-VE, IO-IO, and VEGF treatments. Despite durable outcomes, a subset relapsed and required further therapy. Time to next treatment was prolonged, and IO rechallenge showed meaningful activity. These findings highlight that CR predicts favorable prognosis but does not equate to cure, underscoring the need for continued monitoring. #KidneyCancer @DrChoueiri @DrRanaMcKay @DrDanielHeng @Prof_IanD @drulkav @FDonskov @CPRT65 @CrisSuFe @g_develasco @montypal @crisbergerot @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @HHammersMD @ravikanesvaran @neerajaiims @amerseburger @sonpavde @drenriquegrande @scserendipity1 @Silke_Gillessen @EfstathiouEleni @tompowles1 @BraunMDPhD @nataliagandur @cdanicas @brian_rini @AOmlin #OncoAlertAF @nataliagandur @realbowtiedoc @Onco_Cifu88 @scocmem

Metamizole-induced agranulocytosis resulting in ecthyma gangrenosum after an AI chatbot query | Blood | American Society of Hematology ashpublications.org/blood/article/…

ESMO LATAM is coming soon! I’m proud to be part! Get you place soon!! We will be in Bogotá on Apr 17-18!

Nos enorgullece contarles desde @AIpocrates que uno de nuestros miembros fundadores y amigo personal (compañero de internado): Jaime Alberto González ha asumido como Presidente de la @asocientificas Le deseamos a Jaime el mayor de los éxitos en su gestión, esperando que lleve a las asociaciones a la modernidad y lidere la reoperativizacion sectorial.

🔬Would you spare the bladder if cCR only matches pCR in ~50% of cases? 🗣️Current cCR isn’t reliable enough to guide decisions in MIBC — next-generation response assessment is needed to guide bladder preservation. 👉🏼bjui-journals.onlinelibrary.wiley.com/doi/10.1111/bj…

#EAU26 Dr. Fonteyne on MDT in oligometastatic prostate cancer: Evidence is growing, but context matters. 🔹 STOMP & ORIOLE: MDT → excellent local control, delays progression 🔹 RADIOSA: MDT + ADT > MDT alone for PFS 🔹 ARTO: MDT + SOC improved PFS and may signal OS benefit Yet major gaps remain: • Most data come from metachronous disease • Evidence in de novo oligometastatic HSPC is limited • Patient selection is key @uroweb @UroToday

Updates of IO in NMIBC tríals at #eue2026

Real-world #ProstateCancer treatment patterns in #Colombia. @raymanneh joins @zklaassen_md to discuss a multicenter Colombian analysis highlighting late presentation, high rates of de novo metastatic disease, and low treatment intensification. Limited access to PSA testing and biomarker testing (HRR/MSI) underscores disparities—while tested patients showed better survival—reinforcing the need for Latin American representation and multidisciplinary collaboration in GU oncology. #WatchNow on UroToday > bit.ly/4pF63ZK

Discussion #EAU26 about the future of cystectomy neoadjuvant treatment and radiotherapy in muscle invasive bladder cancer. Things are changing rapidly. With pCR rates >50% for EVP many patients will want to keep their bladders. An era of ‘EVP 1st and ask questions later’ maybe a reality soon. Generation of EVP bladder sparing data is a priority. @Uroweb @EUplatinum

@AndreaNecchi presents the final results of SUNRISE-2 with tar200+IO vs chemoRT showing no benefit of TAR200+IO compared chemoRT. Important negative study! @ASCO #GU26

It is a Phase II trial, It is not too big, but the results are amazing! Congratulations to prof. Maha Hussain! 68 months #GU26 @ASCO

Proud to be part of the most important GU meeting!! #GU26

Felicitaciones a los autores por su Revisión de biología molecular tumoral en la Revista de la Asociación Colombiana de Hematología y Oncología - revista.acho.info/index.php/acho… -

🔈 Tenemos un comunicado importante

Dia mundial por el control del cáncer infantil @INCancerologia @OPSOMS_Col @MinSaludCol

Te esperamos en #Oncolili2026, un espacio de actualización en oncología que propicia el intercambio de conocimiento y la revisión de avances que impactan la práctica clínica. 📆 26 al 28 de febrero de 2026 📌 Auditorio Principal Carlos Ardila Lülle – Torre 5, piso 3 Fundación Valle del Lili Inscríbete: valledellili.org/evento/2o-cong… #FundaciónValleDelLili #TuSaludNuestraPrioridad

Thanks @AACR @INCancerologia Felicitaciones a los investigadores por el control del cáncer